These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 36825430)
1. Detection of MET gene somatic mutations in hepatocellular carcinoma of Egyptian patients using next-generation sequencing. Ahmed E; El-Dien A N; Sabet S; Khalifa M; El Hamshary M Biomarkers; 2023 Jun; 28(4):379-386. PubMed ID: 36825430 [TBL] [Abstract][Full Text] [Related]
2. Personalized circulating tumor DNA in patients with hepatocellular carcinoma: a pilot study. Pommergaard HC; Yde CW; Ahlborn LB; Andersen CL; Henriksen TV; Hasselby JP; Rostved AA; Sørensen CL; Rohrberg KS; Nielsen FC; Rasmussen A Mol Biol Rep; 2022 Feb; 49(2):1609-1616. PubMed ID: 34811635 [TBL] [Abstract][Full Text] [Related]
3. Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma. Howell J; Atkinson SR; Pinato DJ; Knapp S; Ward C; Minisini R; Burlone ME; Leutner M; Pirisi M; Büttner R; Khan SA; Thursz M; Odenthal M; Sharma R Eur J Cancer; 2019 Jul; 116():56-66. PubMed ID: 31173963 [TBL] [Abstract][Full Text] [Related]
4. Prospects and challenges of circulating tumor DNA in precision medicine of hepatocellular carcinoma. Weng J; Atyah M; Zhou C; Ren N Clin Exp Med; 2020 Aug; 20(3):329-337. PubMed ID: 32239299 [TBL] [Abstract][Full Text] [Related]
5. Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics. Ikeda S; Lim JS; Kurzrock R Mol Cancer Ther; 2018 May; 17(5):1114-1122. PubMed ID: 29483209 [TBL] [Abstract][Full Text] [Related]
6. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes. Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618 [TBL] [Abstract][Full Text] [Related]
7. Applications of molecular barcode sequencing for the detection of low-frequency variants in circulating tumour DNA from hepatocellular carcinoma. Lee HW; Kim E; Cho KJ; Park HJ; Seo J; Lee H; Baek E; Choi JR; Han KH; Lee ST; Park JY Liver Int; 2022 Oct; 42(10):2317-2326. PubMed ID: 35776657 [TBL] [Abstract][Full Text] [Related]
8. Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma. Oversoe SK; Clement MS; Weber B; Grønbæk H; Hamilton-Dutoit SJ; Sorensen BS; Kelsen J BMC Cancer; 2021 Apr; 21(1):376. PubMed ID: 33827453 [TBL] [Abstract][Full Text] [Related]
9. Impact of circulating tumor DNA in hepatocellular and pancreatic carcinomas. Dhayat SA; Yang Z J Cancer Res Clin Oncol; 2020 Jul; 146(7):1625-1645. PubMed ID: 32338295 [TBL] [Abstract][Full Text] [Related]
10. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program. Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761 [TBL] [Abstract][Full Text] [Related]
11. Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma. Wu X; Li J; Gassa A; Buchner D; Alakus H; Dong Q; Ren N; Liu M; Odenthal M; Stippel D; Bruns C; Zhao Y; Wahba R Int J Biol Sci; 2020; 16(9):1551-1562. PubMed ID: 32226301 [TBL] [Abstract][Full Text] [Related]
12. The potential, analysis and prospect of ctDNA sequencing in hepatocellular carcinoma. Ding Y; Yao J; Wen M; Liu X; Huang J; Zhang M; Zhang Y; Lv Y; Xie Z; Zuo J PeerJ; 2022; 10():e13473. PubMed ID: 35602894 [TBL] [Abstract][Full Text] [Related]
13. Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma. Ikeda S; Tsigelny IF; Skjevik ÅA; Kono Y; Mendler M; Kuo A; Sicklick JK; Heestand G; Banks KC; Talasaz A; Lanman RB; Lippman S; Kurzrock R Oncologist; 2018 May; 23(5):586-593. PubMed ID: 29487225 [TBL] [Abstract][Full Text] [Related]
14. Genomic Landscape of Liquid Biopsy for Hepatocellular Carcinoma Personalized Medicine. Moldogazieva NT; Zavadskiy SP; Terentiev AA Cancer Genomics Proteomics; 2021; 18(3 Suppl):369-383. PubMed ID: 33994362 [TBL] [Abstract][Full Text] [Related]
15. The Use of ctDNA in the Diagnosis and Monitoring of Hepatocellular Carcinoma-Literature Review. Kopystecka A; Patryn R; Leśniewska M; Budzyńska J; Kozioł I Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298294 [TBL] [Abstract][Full Text] [Related]
16. Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients. Francaviglia I; Magliacane G; Lazzari C; Grassini G; Brunetto E; Dal Cin E; Girlando S; Medicina D; Smart CE; Bulotta A; Gregorc V; Pecciarini L; Doglioni C; Cangi MG Lung Cancer; 2019 Aug; 134():225-232. PubMed ID: 31319985 [TBL] [Abstract][Full Text] [Related]
17. Preferred end coordinates and somatic variants as signatures of circulating tumor DNA associated with hepatocellular carcinoma. Jiang P; Sun K; Tong YK; Cheng SH; Cheng THT; Heung MMS; Wong J; Wong VWS; Chan HLY; Chan KCA; Lo YMD; Chiu RWK Proc Natl Acad Sci U S A; 2018 Nov; 115(46):E10925-E10933. PubMed ID: 30373822 [TBL] [Abstract][Full Text] [Related]
18. Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment. Sogbe M; Bilbao I; Marchese FP; Zazpe J; De Vito A; Pozuelo M; D'Avola D; Iñarrairaegui M; Berasain C; Arechederra M; Argemi J; Sangro B Clin Mol Hepatol; 2024 Apr; 30(2):177-190. PubMed ID: 38163441 [TBL] [Abstract][Full Text] [Related]
19. Correlation of genomic alterations between tumor tissue and circulating tumor DNA by next-generation sequencing. Chang YS; Fang HY; Hung YC; Ke TW; Chang CM; Liu TY; Chen YC; Chao DS; Huang HY; Chang JG J Cancer Res Clin Oncol; 2018 Nov; 144(11):2167-2175. PubMed ID: 30203147 [TBL] [Abstract][Full Text] [Related]
20. Liquid Biopsy Using Cell-Free or Circulating Tumor DNA in the Management of Hepatocellular Carcinoma. Lyu X; Tsui YM; Ho DW; Ng IO Cell Mol Gastroenterol Hepatol; 2022; 13(6):1611-1624. PubMed ID: 35183803 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]